Is tremelimumab beneficial in advanced melanoma?

Journal of Clinical Oncology

Volumn 31, Issue 22, 2013, Pages 2835-2836

  Wilson, Kenneth S ^a   Kotb, Rami ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; IPILIMUMAB; LACTATE DEHYDROGENASE; TICILIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; LETTER; MELANOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; FEMALE; MALE; NOTE; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; SKIN NEOPLASMS;

EID: 84884744256     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.6158     Document Type: Letter

References (4)

1. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
2. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
3. Ribas A, Kefford R, Marshall MA, et al: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616-622, 2013
4. Weber JS: Anti CTLA4 and predictive biomarkers. Ann Oncol 23, 2012 (suppl 9; abstr 71IN)